Countable Labs
United States
- Palo Alto, California
- 29/05/2026
- Unknown
- $26,000,000
In an era of ever-increasing cost and skills required to do complex diagnostics tests, Countable Labs (formerly Enumerix) is developing a next-generation genomics platform to make high resolution biology simple, fast, and affordable. Our goal is to reduce the cost of high resolution tests by at least 10 times to enable access to a broader patient population.
We believe our team is poised to accomplish this. We are a group of seasoned biotech and innovative entrepreneurs, engineers, and scientists with a proven track record of advancing the field of genomics from innovation to commercial success. We have pioneered DNA microarrays, non-invasive prenatal screening using next generation sequencing (NGS), and high-throughput single-cell NGS, and together the founding team holds over 60 granted patents.
- Industry Biotechnology
- Website https://countablelabs.com/
- LinkedIn https://www.linkedin.com/company/countablelabs/
Kubera Health | $6,500,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Volt Harbor Inc. | $2,000,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)
Blulabs | $7,000,000 | (May 29, 2026)